ROME, June 30, 2010 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (OTCBB:IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announced that pregnancy results were released today at the European Society of Human Reproduction & Embryology (ESHRE), a conference which annually attracts thousands of infertility specialists from around the world. Dr Julio Diaz Pinillos, Director of Nacer Reproductive Center in Lima, Peru, reported a 28% clinical pregnancy rate per cycle on the initial 57 cycles using the INVO procedure and mild ovarian stimulation. The INVO procedure uses INVO Bioscience's patented product, the INVOcell which allows for vaginal incubation of eggs, sperm and early embryo development during the infertility treatment process. Dr Julio Diaz Pinillos also reported the birth of Natalia, the first baby conceived in Peru using the INVOcell. Baby Natalia was delivered full term. Natalia and her mother Rosa are doing well. At the same conference, the clinical pregnancy rates of 200 INVO cycles performed from 11 countries was presented; these 200 cases have an average clinical pregnancy rate of 32% per cycle and a multiple pregnancy rate under 12%. "These initial impressive results demonstrate the efficacy and reproducibility of the INVO procedure for the treatment of infertile couples," said INVO Bioscience CEO Kathleen Karloff. About INVO Bioscience INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: INVO Bioscience, Inc. Kathleen Karloff 978-878-9505 www.invobioscience.com